CTKB · Cytek Biosciences, Inc.
$4.45
-0.11 (-2.41%)
At close · Jul 24
Market Cap
$575.98M
Shares
129.14M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$201.49M
+0.5%
FY2025
Net Income
-$66.54M
-1005.3%
FY2025
Gross Margin
51.84%
-3.6pp
FY2025
Operating Margin
-20.04%
-9.8pp
FY2025
Diluted EPS
-$0.09
-550%
FY2023
Operating Cash Flow
-$4.69M
-118.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| $205M – $212M | $204.17M | $201.49MG | $200.45M | $193.02M | $2.96M | $2.18M | $710K | |
| — | $98.61M | $97.03M | $89.35M | $83.59M | $63.06M | $48.81M | $41.13M | |
| — | $105.56M | $104.46M | $111.11M | $109.43M | $100.97M | $79.14M | $51.71M | |
| — | — | 51.84% | 55.43% | 56.69% | 3407.83% | 3628.79% | 7283.1% | |
| — | $36.35M | $36.47M | $39.4M | $44.15M | $34.86M | $24.44M | $13.69M | |
| — | $48.58M | $49.44M | $49.11M | $49.15M | $33.23M | $24.71M | $14.99M | |
| — | $64.51M | $58.94M | $43.11M | $43.97M | $34.69M | $20.84M | $9.37M | |
| — | $3.7M | $3.7M | $3.7M | $3.2M | $800K | $300K | $71K | |
| — | — | $7.58M | $7.21M | $6.05M | $2.49M | $1.24M | $603K | |
| — | $149.43M | $144.84M | $131.63M | $137.27M | $102.78M | $69.99M | $38.05M | |
| — | -$43.87M | -$40.38M | -$20.52M | -$27.85M | -$1.8M | $9.16M | $13.66M | |
| — | — | -20.04% | -10.24% | -14.43% | -60.88% | 419.85% | 1923.8% | |
| — | — | -$32.81M | -$13.31M | -$21.8M | $688K | $10.4M | $14.26M | |
| — | $445K | $474K | -$5.24M | $2.07M | $2.57M | $1.74M | $333K | |
| — | $2.5M | $2.22M | $5.12M | $6.41M | $4.62M | $49K | $110K | |
| — | $7.92M | $10.54M | $14.82M | $12.14M | $3.06M | -$3.22M | $771K | |
| — | — | -$29.84M | -$5.7M | -$15.71M | $1.26M | $5.94M | $14.43M | |
| — | $38.06M | $36.7M | $320K | -$3.56M | -$1.22M | $2.91M | -$4.98M | |
| — | -$74M | -$66.54M | -$6.02M | -$12.15M | $2.48M | $3.03M | $19.41M | |
| — | — | -33.02% | -3% | -6.29% | 83.83% | 138.79% | 2733.94% | |
| — | — | $0 | $0 | $0 | -$92K | $26K | $0 | |
| — | -$74M | -$66.54M | -$6.02M | -$12.15M | $2.58M | $0 | $3.22M | |
| — | -$71.03M | -$64.31M | -$4.73M | -$12.73M | $890K | $3.86M | $19.62M | |
| USD/shares | — | — | — | — | -$0.09 | $0.02 | $0.00 | $0.11 |
| USD/shares | — | — | — | — | -$0.09 | $0.02 | $0.00 | $0.10 |
| shares | — | — | 127.75M | 130.61M | 135.28M | 134.51M | 76.74M | 29.13M |
| shares | — | — | 127.75M | 130.61M | 135.28M | 138.56M | 81.54M | 32.6M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2025: $146.56M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.14×
EV/EBIT
—
Medical Devices median 21.03×
P/E (TTM)
—
Medical Devices median 27.62×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $201,493,000 | $200,453,000 | $193,015,000 | $164,036,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| United States | $95,250,000 | $92,610,000 | $102,085,000 | $94,592,000 | $72,724,000 | $55,477,000 |
| EMEA | $55,883,000 | $62,341,000 | $53,178,000 | $43,958,000 | $36,967,000 | $25,912,000 |
| Asia Pacific | $41,080,000 | $35,770,000 | $31,598,000 | $22,523,000 | $16,078,000 | $10,740,000 |
| China | $20,500,000 | — | — | — | — | — |
| Other | $9,280,000 | $9,732,000 | $6,154,000 | $2,963,000 | $127,950,000 | $92,839,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $144,233,000 | $153,263,000 | $156,717,000 | $148,600,000 | $119,519,000 | $85,283,000 |
| Service | $57,260,000 | $47,190,000 | $36,298,000 | $15,436,000 | $8,431,000 | $7,556,000 |
Key facts
CIK
1831915
CUSIP
23285D109
13F (30d)
20 filings
20 filers
Visit website
Investor relations